Wednesday, July 8, 2026

Patent intelligence · US

US 9796976

Methods and compositions for modulating alpha-1 antitrypsin expression

granted A61KA61K31/7115A61K31/712A61K31/7125
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 222
Patent details — US 9796976
Jurisdiction
US
Status
granted
Grant date
Oct 24, 2017
Expiration
Oct 19, 2037
Claims
18
CPC classes
A61K, A61K31/7115, A61K31/712, A61K31/7125
View on Google Patents ↗

Quick answer

US 9796976 (Methods and compositions for modulating alpha-1 antitrypsin expression) is held by Ionis Pharmaceuticals, Inc.. Status: granted. Granted Oct 24, 2017. Expires Oct 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
18
CPC classes
A61K, A61K31/7115, A61K31/712, A61K31/7125

More from Ionis Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12409188

    Modulators of HSD17B13 expression

    Ionis Pharmaceuticals, Inc. · Expires Sep 4, 2045

    granted
  2. US 12410225

    Modulation of dendritic cell lineages

    Orionis Biosciences, Inc · Expires Sep 4, 2045

    granted
  3. US 12410430

    Modulating apolipoprotein (A) expression

    Ionis Pharmaceuticals, Inc. · Expires Sep 4, 2045

    granted
  4. US 12364753

    CD8 binding agents

    Orionis Biosciences, Inc · Expires Jul 17, 2045

    granted
  5. US 12351633

    PD-1 and PD-L1 binding agents

    Orionis Biosciences, Inc · Expires Jul 3, 2045

    granted
  6. US 12350285

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Expires Jul 3, 2045

    granted
  7. US 12351614

    CLEC9A-based chimeric protein complexes

    Orionis Biosciences, Inc · Expires Jul 3, 2045

    granted
  8. US 12343357

    Compositions and methods for modulating MECP2 expression

    Ionis Pharmaceuticals, Inc. · Expires Jun 26, 2045

    granted

Frequently asked questions

What is US patent 9796976?

US 9796976 (Methods and compositions for modulating alpha-1 antitrypsin expression) is held by Ionis Pharmaceuticals, Inc.. Status: granted. Granted Oct 24, 2017. Expires Oct 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9796976?

Ionis Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 222 pharmaceutical patents for this assignee.

When does US 9796976 expire?

Our index shows an expiration date of Oct 19, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.